FDA Updates Human Factors Guidance: What Medical Device Manufacturers Need to Know
- 5 days ago
- 3 min read
The FDA has issued an updated guidance on Applying Human Factors and Usability Engineering (HFE/UE) to Medical Devices, providing manufacturers with a clearer framework for designing devices that can be used safely and effectively by their intended users.
The updated guidance was issued on August 3, 2026, replacing the original 2016 guidance. While the document contains nonbinding recommendations, it reflects the FDA’s current thinking on human factors engineering and usability engineering for medical devices.
Beyond “Does the Device Work?”
A medical device can perform exactly as intended from a technical perspective and still create safety risks if users misunderstand, misinterpret, or incorrectly interact with it.
The FDA emphasizes that human factors should therefore be integrated into device design, development, and risk management—not treated as a final usability check before submission. Manufacturers are encouraged to consider three interconnected elements throughout development:
Who will use the device
Where and under what conditions it will be used
How users will interact with the device and its user interface
This includes controls, displays, alarms, software interfaces, packaging, labeling, instructions for use, and training materials.
Identify Critical Tasks Early
One of the key concepts in the guidance is the identification of critical tasks—tasks where an incorrect or missed action could result in serious harm to the patient or user.
Manufacturers can use approaches such as:
Task analysis
FMEA and fault tree analysis
Heuristic evaluation
Expert review
Interviews and contextual inquiry
Formative evaluations
Importantly, the FDA recognizes that analytical assessments alone may not reveal every potential use error. Observing representative users interacting with prototypes or simulated-use environments can uncover problems that development teams may not anticipate.
Design Out the Risk Whenever Possible
A particularly important takeaway is the FDA’s emphasis on design-based risk control.
When a use-related hazard is identified, manufacturers should first consider whether the risk can be eliminated or reduced through the device or user-interface design. Protective measures, warnings, labeling, and training can provide additional controls, but they are generally less preferred because they depend on users remembering or accessing information during use.
In practical terms:
Better design → fewer use errors → safer device use.
Formative Evaluation Should Happen Before Human Factors Validation
Formative evaluation allows manufacturers to identify usability problems while the device is still being developed.
The FDA recommends using these evaluations iteratively to identify previously unrecognized use errors, refine the user interface, assess risk controls, determine training needs, and prepare for human factors validation.
Finding and correcting usability problems during development is generally much easier and less costly than discovering major design deficiencies during final validation.
What Does Human Factors Validation Need to Demonstrate?
Human factors validation testing should represent realistic use of the final device by representative intended users.
The FDA highlights four important considerations:
1. Representative users - Participants should reflect the actual intended user populations.
2. Critical tasks - All identified critical tasks should be included.
3. Final user interface - The tested device should represent the final design.
4. Realistic use conditions - The test environment should adequately represent actual conditions of use.
For human factors validation testing, the FDA states that the minimum number of participants should generally be 15, with at least 15 participants for each distinct user population when multiple distinct populations exist. The appropriate sample size may be higher depending on the device and user populations.
Training Alone Is Not Always the Answer
Another important point for manufacturers is that additional user training should not automatically be treated as the solution to a use-related safety problem.
If validation identifies a critical use error, simply stating that users will receive more training or improved instructions may not be sufficient. Additional evidence may be needed to demonstrate that the proposed intervention actually reduces the risk to an acceptable level.
What This Means for MedTech Companies
The updated guidance reinforces an important principle:
Human factors is a design and risk-management activity—not simply a testing activity.
Manufacturers should consider HFE/UE from the early stages of product development, continuously connect it with risk management, and document how user-related hazards were identified, controlled, and validated.
For medical device companies preparing for FDA submissions, developing new products, or modifying existing devices, integrating human factors early can help identify usability problems before they become expensive regulatory or product-development challenges.
How Can Spiral Medical Development Help?
At Spiral Medical Development, we support medical device companies with regulatory, quality, clinical, and product-development needs—including human factors/usability considerations, risk management, design controls, CER writing, QMS implementation, and regulatory training.
If your team is developing a medical device or preparing for an FDA submission and wants a deeper understanding of how human factors should fit into your development and risk-management processes, let’s connect for a quick discovery call.
Source: FDA, “Applying Human Factors and Usability Engineering to Medical Devices,” guidance issued August 3, 2026. The guidance contains nonbinding recommendations and reflects the FDA’s current thinking.
Comments